A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

Study Overview

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.

Study Description

A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics, and Antiviral Activity of PGDM 1400 and PGT 121 Monoclonal Antibodies in HIV-infected Adults

  • ClinicalTrials.gov Identifier: NCT03205917
  • Protocol Number: 2017P000232
  • Principal Investigator: Boris Juelg

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000